# Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors

> **NCT07041112** · — · COMPLETED · sponsor: **Juan Ruano Ruiz** · enrollment: 1000 (actual)

## Conditions studied

- Psoriasis
- Psoriatic Arthritis (PsA)
- Cardiovascular Risk Factors
- Metabolic Syndrome (MetS)
- Drug Survival
- Pharmacogenetics

## Interventions

- **DRUG:** Biologic therapy for psoriasis

## Key facts

- **NCT ID:** NCT07041112
- **Lead sponsor:** Juan Ruano Ruiz
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07041112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07041112, "Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07041112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*